In recognition of the need for pioneers to produce new alternatives and hope against the HIV/AIDS pandemic,GlaxoSmithKline (GSK) is offering $500,000 in unrestricted awards for innovative HIV/AIDS drug research.
Applications are now being solicited for 2002 awards and must be submitted by July 31. The one-time awards are from $25,000 to $150,000 and are intended to further the development of inventive treatments for HIV/AIDS, including therapies aimed at treating infection as well as prophylactic vaccines or microbicides designed to prevent transmission of the virus.
Award recipients will be chosen by three leading independent AIDS researchers. For detailed information about the GSK Drug Discovery and Development Award, as well as an application, please call 1-888-527-6935.
"Science and medicine have made incredible advances in the treatment of people living with HIV in the last decade, and providing support to researchers is key to keeping things moving forward," said Doug Manion, M.D., vice president of clinical development for GSK. "We are supportive of researchers in the scientific community in their ceaseless goal of finding new solutions to drug-resistance and viral mutation, the spread of the virus and simplification of treatment, and who are working towards the eradication of HIV and AIDS."
The award carries no obligation to the recipient's organization for licensure, patenting or transfer of confidential information, although GSK may discuss the possibility of future collaboration with some applicants.
An Expert Review Board comprised of acknowledged leaders in the field of HIV/AIDS will independently judge and choose the award recipients. Although GSK will be able to review proposals, it will not be involved in the selection of recipients.
For purposes of the award program, the judges will define "drug discovery and development" as one or more of the following: